ArticlePest management science2025
A new mutation in the octopamine receptor associated with amitraz resistance in Varroa destructor.
Article in Pest management science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Virus specific impacts on honey bee flight performance are mediated by the octopamine pathway.bioRxiv : the preprint server for biology · 2026Article
- Insight into the Prospects of RNA Interference for Honey Bee Pathogens and Parasite Control.Insects · 2026Review
- RNAi targeting ABCB1-like efflux transporters improves miticide efficacy in resistant Varroa mites.Parasites & vectors · 2026Article
- Evaluation of late-season Varroa destructor treatments and their impact on amitraz resistant mite populations.Scientific reports · 2026Article
- Snapback high resolution melting analysis for the rapid detection and differentiation of the L925 mutations associated with resistance to synthetic pyrethroids in Varroa destructor.Experimental & applied acarology · 2026Article
- Toxicity of oxalic acid and its toxic effect on antioxidative enzymes in honey bee larvae.Veterinarni medicina · 2025Article
- Sensitivity and Resistance of Parasitic Mites (Insects · 2025Review
- Arising amitraz and pyrethroids resistance mutations in the ectoparasitic Varroa destructor mite in Canada.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe acaricide amitraz is now used intensively in many regions to control the honey bee parasite, Varroa destructor, because of the reduced efficacy of pyrethroids and coumaphos caused by resistance evolution. The continued application of amitraz in recent years exerts a very high selection pressure on mites, favouring the evolution of resistance to this acaricide. Mutations N87S and Y215H in the β2-adrenergic-like octopamine receptor (Octβ2R), target site of amitraz, have been already associated with resistance to amitraz in France and the USA, respectively.
resultsA new mutation (F290L) in the Octβ2R of V. destructor has been found in mites from Spanish apiaries. The frequency of L290 mutated alleles in colonies increased after consecutive treatments with amitraz. In a field trial, mites from colonies with higher frequency of L290 mutated allele took longer to die compared with those carrying a higher proportion of the wild-type allele. Lower susceptibility to amitraz was found in apiaries with a high frequency of homozygous mutants.
conclusionOur data indicate the association of the F290L mutation in the octopamine receptor with resistance to amitraz in Spanish populations of V. destructor. Determining the frequency of mutant mites in apiaries may be important for predicting the efficacy of amitraz treatment in the field and would help design appropriate resistance management. © 2024 The Author(s). Pest Management Science published by John Wiley & Sons Ltd on behalf of Society of Chemical Industry.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.